156 related articles for article (PubMed ID: 27578827)
41. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma.
Bastos AU; Oler G; Nozima BH; Moysés RA; Cerutti JM
Eur J Endocrinol; 2015 Oct; 173(4):525-40. PubMed ID: 26338373
[TBL] [Abstract][Full Text] [Related]
42. Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer.
Shi X; Liu R; Qu S; Zhu G; Bishop J; Liu X; Sun H; Shan Z; Wang E; Luo Y; Yang X; Zhao J; Du J; El-Naggar AK; Teng W; Xing M
J Clin Endocrinol Metab; 2015 Apr; 100(4):E632-7. PubMed ID: 25584719
[TBL] [Abstract][Full Text] [Related]
43. Functional characterization of the novel T599I-VKSRdel BRAF mutation in a follicular variant papillary thyroid carcinoma.
De Falco V; Giannini R; Tamburrino A; Ugolini C; Lupi C; Puxeddu E; Santoro M; Basolo F
J Clin Endocrinol Metab; 2008 Nov; 93(11):4398-402. PubMed ID: 18697864
[TBL] [Abstract][Full Text] [Related]
44. Low frequency of TERT promoter mutations in a series of well-differentiated follicular-patterned thyroid neoplasms.
Proietti A; Sartori C; Macerola E; Borrelli N; Materazzi G; Vitti P; Basolo F
Virchows Arch; 2017 Dec; 471(6):769-773. PubMed ID: 28975450
[TBL] [Abstract][Full Text] [Related]
45. An update on molecular biology of thyroid cancers.
Omur O; Baran Y
Crit Rev Oncol Hematol; 2014 Jun; 90(3):233-52. PubMed ID: 24405857
[TBL] [Abstract][Full Text] [Related]
46. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E
Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937
[TBL] [Abstract][Full Text] [Related]
47. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane.
Riesco-Eizaguirre G; Gutiérrez-Martínez P; García-Cabezas MA; Nistal M; Santisteban P
Endocr Relat Cancer; 2006 Mar; 13(1):257-69. PubMed ID: 16601293
[TBL] [Abstract][Full Text] [Related]
48. BRAF mutation in thyroid cancer.
Xing M
Endocr Relat Cancer; 2005 Jun; 12(2):245-62. PubMed ID: 15947100
[TBL] [Abstract][Full Text] [Related]
49. Histopathologic and Clinical Characterization of Thyroid Tumors Carrying the BRAF(K601E) Mutation.
Afkhami M; Karunamurthy A; Chiosea S; Nikiforova MN; Seethala R; Nikiforov YE; Coyne C
Thyroid; 2016 Feb; 26(2):242-7. PubMed ID: 26422023
[TBL] [Abstract][Full Text] [Related]
50. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma.
Kim TY; Kim WB; Song JY; Rhee YS; Gong G; Cho YM; Kim SY; Kim SC; Hong SJ; Shong YK
Clin Endocrinol (Oxf); 2005 Nov; 63(5):588-93. PubMed ID: 16268813
[TBL] [Abstract][Full Text] [Related]
51. Follicular variant of papillary thyroid carcinoma: a diagnostic challenge for clinicians and pathologists.
Salajegheh A; Petcu EB; Smith RA; Lam AK
Postgrad Med J; 2008 Feb; 84(988):78-82. PubMed ID: 18322127
[TBL] [Abstract][Full Text] [Related]
52. Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies.
Landa I; Pozdeyev N; Korch C; Marlow LA; Smallridge RC; Copland JA; Henderson YC; Lai SY; Clayman GL; Onoda N; Tan AC; Garcia-Rendueles MER; Knauf JA; Haugen BR; Fagin JA; Schweppe RE
Clin Cancer Res; 2019 May; 25(10):3141-3151. PubMed ID: 30737244
[TBL] [Abstract][Full Text] [Related]
53. The role of the size in thyroid cancer risk stratification.
Vianello F; Censi S; Watutantrige-Fernando S; Barollo S; Zhu YH; Albiger N; Bertazza L; Manso J; Carducci S; Benna C; Iacobone M; Galuppini F; Pennelli G; Mian C
Sci Rep; 2021 Mar; 11(1):7303. PubMed ID: 33790328
[TBL] [Abstract][Full Text] [Related]
54. Molecular pathology of thyroid cancer: diagnostic and clinical implications.
Fagin JA; Mitsiades N
Best Pract Res Clin Endocrinol Metab; 2008 Dec; 22(6):955-69. PubMed ID: 19041825
[TBL] [Abstract][Full Text] [Related]
55. Molecular perspectives in differentiated thyroid cancer.
Buffet C; Groussin L
Ann Endocrinol (Paris); 2015 Feb; 76(1 Suppl 1):1S8-15. PubMed ID: 26826484
[TBL] [Abstract][Full Text] [Related]
56. Age-associated mortality is partially mediated by TERT promoter mutation status in differentiated thyroid carcinoma.
Heo J; Lee S; Park J; Yang H; Park H; Ki CS; Oh YL; Kim HI; Kim SW; Chung JH; Kim K; Kim TH
PLoS One; 2023; 18(11):e0294145. PubMed ID: 37948420
[TBL] [Abstract][Full Text] [Related]
57. Genetic-guided Risk Assessment and Management of Thyroid Cancer.
Xing M
Endocrinol Metab Clin North Am; 2019 Mar; 48(1):109-124. PubMed ID: 30717896
[TBL] [Abstract][Full Text] [Related]
58. Additional Oncogenic Alterations in RAS-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes.
Bikas A; Ahmadi S; Pappa T; Marqusee E; Wong K; Nehs MA; Cho NL; Haase J; Doherty GM; Sehgal K; Barletta JA; Alexander EK; Landa I
Clin Cancer Res; 2023 Jul; 29(14):2678-2685. PubMed ID: 37260297
[TBL] [Abstract][Full Text] [Related]
59. Clinical relevance of gene mutations and rearrangements in advanced differentiated thyroid cancer.
Nannini M; Repaci A; Nigro MC; Colapinto A; Vicennati V; Maloberti T; Gruppioni E; Altimari A; Solaroli E; Lodi Rizzini E; Monari F; De Leo A; Damiani S; Pagotto U; Pantaleo MA; de Biase D; Tallini G
ESMO Open; 2023 Dec; 8(6):102039. PubMed ID: 37879236
[TBL] [Abstract][Full Text] [Related]
60. The prognostic power of gene mutations in thyroid cancer.
Ahmadi S; Landa I
Endocr Connect; 2024 Feb; 13(2):. PubMed ID: 38078934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
